company background image

KemPharm NasdaqGS:KMPH Stock Report

Last Price


Market Cap







02 Oct, 2022


Company Financials +
KMPH fundamental analysis
Snowflake Score
Future Growth6/6
Past Performance0/6
Financial Health5/6

KMPH Stock Overview

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.

KemPharm Competitors

Price History & Performance

Summary of all time highs, changes and price drops for KemPharm
Historical stock prices
Current Share PriceUS$6.24
52 Week HighUS$10.80
52 Week LowUS$4.00
1 Month Change11.23%
3 Month Change38.67%
1 Year Change-32.83%
3 Year Change-42.65%
5 Year Change-89.67%
Change since IPO-96.52%

Recent News & Updates

Sep 28

KemPharm posts Phase 1 data to support further studies for sleep disorder therapy

KemPharm, Inc. (NASDAQ:KMPH), a company developing prodrug versions of FDA-approved drugs, announced Wednesday early results from a Phase 1 trial to support further studies for lead asset KP1077 in sleep-related disorders. The Phase 1 open-label trial involving 15 volunteers was designed to evaluate single doses of 80 mg and 200 mg of serdexmethylphenidate (SDX), a prodrug of d-methylphenidate (d-MPH) and the only active pharmaceutical ingredient (API) in KP1077. The investigators compared SDX's cardiovascular effects and pharmacokinetics against immediate-release and long-acting formulations of Ritalin (racemic methylphenidate), a commonly used CNS stimulant. Citing the topline data, KMPH said that the initial dosing levels it has selected for the Phase 2 trial for KP1077 would be well tolerated leading to higher exposure to d-MPH compared to existing methylphenidate products. Before the year-end, the company plans to start a mid-stage trial for KP1077 in idiopathic hypersomnia, a rare sleep disorder. Another study is expected to begin in 2023, targeting patients with narcolepsy. Read more on the upcoming catalysts for KMPH as outlined by the management in August.

Sep 15

KemPharm wins Buy rating at Canaccord on CNS focus

Canaccord Genuity has launched its coverage on KemPharm, Inc. (NASDAQ:KMPH), a developer of enhanced versions of existing medications, with a Buy recommendation, noting its renewed-focused on rare diseases linked to the central nervous system (CNS). The analysts Sumant Kulkarni and Kyle Qian highlight the company’s recent acquisition of arimoclomol, an experimental therapy targeted at rare progressive neurodegenerative disease Niemann-Pick disease type C. The transaction, along with KMPH’s ongoing studies for KP1077 for idiopathic hypersomnia, “signal a well-crafted/ clear strategy to deepen its presence in central nervous system (CNS) focused rare diseases,” the analysts wrote. The firm, with a $20 per share target on KMPH, added that the company’s strategy to focus on rare CNS diseases is underappreciated and calls the deal for arimoclomol a “strategically and financially prudent” move with the potential for speedier cash flow generation. While KP1077 is poised to become a differentiated option for IH, where there is limited competition, the analysts also highlight the prospects for royalties from KMPH’s ADHD drug Azstarys and the company’s cash runway that extends beyond 2025.

Shareholder Returns

KMPHUS PharmaceuticalsUS Market

Return vs Industry: KMPH underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: KMPH underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is KMPH's price volatile compared to industry and market?
KMPH volatility
KMPH Average Weekly Movement9.5%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: KMPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: KMPH's weekly volatility (9%) has been stable over the past year.

About the Company

200624Travis Mickle

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).

KemPharm Fundamentals Summary

How do KemPharm's earnings and revenue compare to its market cap?
KMPH fundamental statistics
Market CapUS$215.24m
Earnings (TTM)-US$30.37m
Revenue (TTM)US$9.81m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KMPH income statement (TTM)
Cost of RevenueUS$118.00k
Gross ProfitUS$9.69m
Other ExpensesUS$40.06m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.88
Gross Margin98.80%
Net Profit Margin-309.50%
Debt/Equity Ratio14.7%

How did KMPH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is KMPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KMPH?

Other financial metrics that can be useful for relative valuation.

KMPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue15.3x
Enterprise Value/EBITDA-11x
PEG Ration/a

Price to Sales Ratio vs Peers

How does KMPH's PS Ratio compare to its peers?

KMPH PS Ratio vs Peers
The above table shows the PS ratio for KMPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average9.9x
EYPT EyePoint Pharmaceuticals
LQDA Liquidia
OPTN OptiNose
HROW Harrow Health
KMPH KemPharm

Price-To-Sales vs Peers: KMPH is expensive based on its Price-To-Sales Ratio (21.9x) compared to the peer average (9.9x).

Price to Earnings Ratio vs Industry

How does KMPH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: KMPH is expensive based on its Price-To-Sales Ratio (21.9x) compared to the US Pharmaceuticals industry average (2.9x)

Price to Sales Ratio vs Fair Ratio

What is KMPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KMPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio21.9x
Fair PS Ratio15.9x

Price-To-Sales vs Fair Ratio: KMPH is expensive based on its Price-To-Sales Ratio (21.9x) compared to the estimated Fair Price-To-Sales Ratio (15.9x).

Share Price vs Fair Value

What is the Fair Price of KMPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KMPH ($6.24) is trading below our estimate of fair value ($91.2)

Significantly Below Fair Value: KMPH is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is KemPharm forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score


Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KMPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: KMPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: KMPH is expected to become profitable in the next 3 years.

Revenue vs Market: KMPH's revenue (52.7% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: KMPH's revenue (52.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: KMPH's Return on Equity is forecast to be high in 3 years time (23.6%)

Discover growth companies

Past Performance

How has KemPharm performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: KMPH is currently unprofitable.

Growing Profit Margin: KMPH is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: KMPH is unprofitable, but has reduced losses over the past 5 years at a rate of 5.9% per year.

Accelerating Growth: Unable to compare KMPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KMPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).

Return on Equity

High ROE: KMPH has a negative Return on Equity (-30.6%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is KemPharm's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: KMPH's short term assets ($87.4M) exceed its short term liabilities ($7.2M).

Long Term Liabilities: KMPH's short term assets ($87.4M) exceed its long term liabilities ($17.9M).

Debt to Equity History and Analysis

Debt Level: KMPH has more cash than its total debt.

Reducing Debt: KMPH had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KMPH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if KMPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is KemPharm current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

KemPharm Dividend Yield vs Market
How does KemPharm dividend yield compare to the market?
SegmentDividend Yield
Company (KemPharm)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (KemPharm)n/a

Notable Dividend: Unable to evaluate KMPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KMPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KMPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KMPH's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KMPH has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Travis Mickle (49 yo)





Dr. Travis C. Mickle, Ph D., Co-founded KemPharm, Inc. in 2006 and has been its President since 2006, Chief Executive Officer since October 2010 and was its Chairman since November 2014 until November 2021...

CEO Compensation Analysis

Travis Mickle's Compensation vs KemPharm Earnings
How has Travis Mickle's remuneration changed compared to KemPharm's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$3mUS$562k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$968kUS$530k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$1mUS$528k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$1mUS$513k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$1mUS$500k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$2mUS$496k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$4mUS$458k


Compensation vs Market: Travis's total compensation ($USD2.66M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Travis's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: KMPH's management team is seasoned and experienced (6.5 years average tenure).

Board Members

Experienced Board: KMPH's board of directors are considered experienced (9 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqGS:KMPH Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 May 22BuyUS$13,096Travis MickleIndividual3,000US$4.39
25 May 22BuyUS$43,900Mickle Investments LLCCompany10,000US$4.39
25 May 22BuyUS$8,780David TierneyIndividual2,000US$4.39
20 May 22BuyUS$974Tamara SeymourIndividual200US$4.87
18 May 22BuyUS$5,999R. CliftonIndividual1,200US$5.00
18 May 22BuyUS$24,608Richard PascoeIndividual5,000US$4.94
18 May 22BuyUS$24,780Matthew PloosterIndividual5,000US$4.97
30 Nov 21BuyUS$15,578David TierneyIndividual2,000US$7.79
30 Nov 21BuyUS$11,822Richard PascoeIndividual1,500US$7.88
18 Nov 21BuyUS$4,228R. CliftonIndividual510US$8.29
18 Nov 21BuyUS$18,516Travis MickleIndividual2,250US$8.23

Ownership Breakdown

What is the ownership structure of KMPH?
Owner TypeNumber of SharesOwnership Percentage
Private Companies11,0340.03%
Individual Insiders3,916,30711.4%
General Public22,437,48665.0%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 31.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Samuel Braun
3,021,660$18.9m0%no data
The Vanguard Group, Inc.
1,380,638$8.6m-8.98%no data
BlackRock, Inc.
852,849$5.3m-62.15%no data
Daniel Mangless
700,000$4.4m0%no data
HealthInvest Partners AB
Laurion Capital Management LP
Janney Montgomery Scott LLC, Asset Management Arm
Auctus Fund Management, LLC
Millennium Management LLC
337,247$2.1m5.3%no data
Geode Capital Management, LLC
318,231$2.0m-41.22%no data
Sabby Management, LLC
The Retirement Planning Company of New England, Inc
Delaware Street Capital, L.L.C.
Susquehanna International Group, LLP, Asset Management Arm
163,901$1.0m-13.26%no data
Mystic Asset Management
Ergoteles LLC
Travis Mickle
135,674$846.6k2.26%no data
BNY Mellon Asset Management
118,166$737.4k-27.78%no data
AQR Capital Management, LLC
107,341$669.8k-48.91%no data
Renaissance Technologies LLC
103,394$645.2k-42.81%no data
State Street Global Advisors, Inc.
102,640$640.5k-81.39%no data
DIMlux S.A.
Kovack Advisors, Inc., Asset Management Arm
Arete Wealth Advisors, LLC
Martingale Asset Management, L.P.

Company Information

KemPharm, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: KemPharm, Inc.
  • Ticker: KMPH
  • Exchange: NasdaqGS
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$215.240m
  • Shares outstanding: 34.49m
  • Website:

Number of Employees


  • KemPharm, Inc.
  • 1180 Celebration Boulevard
  • Suite 103
  • Celebration
  • Florida
  • 34747
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KMPHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2015
1GDDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2015

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.